|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ALG12 |
Gene summary for ALG12 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ALG12 | Gene ID | 79087 |
| Gene name | ALG12 alpha-1,6-mannosyltransferase | |
| Gene Alias | CDG1G | |
| Cytomap | 22q13.33 | |
| Gene Type | protein-coding | GO ID | GO:0006457 | UniProtAcc | A0A024R4V6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79087 | ALG12 | LZE2T | Human | Esophagus | ESCC | 6.36e-03 | 3.04e-01 | 0.082 |
| 79087 | ALG12 | LZE4T | Human | Esophagus | ESCC | 3.31e-06 | 1.73e-01 | 0.0811 |
| 79087 | ALG12 | LZE7T | Human | Esophagus | ESCC | 4.93e-05 | 2.25e-01 | 0.0667 |
| 79087 | ALG12 | LZE8T | Human | Esophagus | ESCC | 2.06e-02 | 1.42e-01 | 0.067 |
| 79087 | ALG12 | LZE20T | Human | Esophagus | ESCC | 2.82e-02 | 1.06e-01 | 0.0662 |
| 79087 | ALG12 | LZE24T | Human | Esophagus | ESCC | 2.97e-15 | 3.20e-01 | 0.0596 |
| 79087 | ALG12 | LZE6T | Human | Esophagus | ESCC | 1.95e-03 | 1.13e-01 | 0.0845 |
| 79087 | ALG12 | P1T-E | Human | Esophagus | ESCC | 1.90e-04 | 2.19e-01 | 0.0875 |
| 79087 | ALG12 | P2T-E | Human | Esophagus | ESCC | 4.17e-22 | 3.77e-01 | 0.1177 |
| 79087 | ALG12 | P4T-E | Human | Esophagus | ESCC | 1.13e-21 | 3.28e-01 | 0.1323 |
| 79087 | ALG12 | P5T-E | Human | Esophagus | ESCC | 1.38e-14 | 2.44e-01 | 0.1327 |
| 79087 | ALG12 | P8T-E | Human | Esophagus | ESCC | 4.32e-10 | 1.63e-01 | 0.0889 |
| 79087 | ALG12 | P9T-E | Human | Esophagus | ESCC | 6.83e-09 | 2.37e-01 | 0.1131 |
| 79087 | ALG12 | P10T-E | Human | Esophagus | ESCC | 6.75e-20 | 3.71e-01 | 0.116 |
| 79087 | ALG12 | P11T-E | Human | Esophagus | ESCC | 8.39e-17 | 6.78e-01 | 0.1426 |
| 79087 | ALG12 | P12T-E | Human | Esophagus | ESCC | 1.48e-27 | 4.71e-01 | 0.1122 |
| 79087 | ALG12 | P15T-E | Human | Esophagus | ESCC | 2.31e-22 | 3.66e-01 | 0.1149 |
| 79087 | ALG12 | P16T-E | Human | Esophagus | ESCC | 2.57e-27 | 6.11e-01 | 0.1153 |
| 79087 | ALG12 | P17T-E | Human | Esophagus | ESCC | 4.61e-10 | 3.97e-01 | 0.1278 |
| 79087 | ALG12 | P19T-E | Human | Esophagus | ESCC | 2.49e-05 | 4.60e-01 | 0.1662 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006457110 | Esophagus | ESCC | protein folding | 163/8552 | 212/18723 | 1.13e-20 | 1.74e-18 | 163 |
| GO:000648714 | Esophagus | ESCC | protein N-linked glycosylation | 51/8552 | 65/18723 | 6.41e-08 | 1.13e-06 | 51 |
| GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
| GO:00700854 | Esophagus | ESCC | glycosylation | 144/8552 | 240/18723 | 5.12e-06 | 5.38e-05 | 144 |
| GO:00064865 | Esophagus | ESCC | protein glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00434135 | Esophagus | ESCC | macromolecule glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
| GO:00064882 | Esophagus | ESCC | dolichol-linked oligosaccharide biosynthetic process | 14/8552 | 18/18723 | 5.77e-03 | 2.14e-02 | 14 |
| GO:00064902 | Esophagus | ESCC | oligosaccharide-lipid intermediate biosynthetic process | 14/8552 | 19/18723 | 1.27e-02 | 4.21e-02 | 14 |
| GO:00064577 | Liver | Cirrhotic | protein folding | 114/4634 | 212/18723 | 9.23e-20 | 2.31e-17 | 114 |
| GO:00064873 | Liver | Cirrhotic | protein N-linked glycosylation | 30/4634 | 65/18723 | 1.40e-04 | 1.36e-03 | 30 |
| GO:000645712 | Liver | HCC | protein folding | 160/7958 | 212/18723 | 1.07e-22 | 1.88e-20 | 160 |
| GO:000648711 | Liver | HCC | protein N-linked glycosylation | 48/7958 | 65/18723 | 2.85e-07 | 5.00e-06 | 48 |
| GO:00064862 | Liver | HCC | protein glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
| GO:00434132 | Liver | HCC | macromolecule glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
| GO:00700852 | Liver | HCC | glycosylation | 128/7958 | 240/18723 | 4.35e-04 | 2.92e-03 | 128 |
| GO:0009100 | Liver | HCC | glycoprotein metabolic process | 193/7958 | 387/18723 | 1.89e-03 | 9.62e-03 | 193 |
| GO:000645718 | Oral cavity | OSCC | protein folding | 154/7305 | 212/18723 | 1.89e-23 | 4.60e-21 | 154 |
| GO:00064875 | Oral cavity | OSCC | protein N-linked glycosylation | 44/7305 | 65/18723 | 2.63e-06 | 3.26e-05 | 44 |
| GO:0006488 | Oral cavity | OSCC | dolichol-linked oligosaccharide biosynthetic process | 15/7305 | 18/18723 | 1.53e-04 | 1.07e-03 | 15 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa005104 | Liver | Cirrhotic | N-Glycan biosynthesis | 32/2530 | 53/8465 | 3.82e-06 | 4.10e-05 | 2.53e-05 | 32 |
| hsa005134 | Liver | Cirrhotic | Various types of N-glycan biosynthesis | 26/2530 | 42/8465 | 1.65e-05 | 1.41e-04 | 8.69e-05 | 26 |
| hsa0051011 | Liver | Cirrhotic | N-Glycan biosynthesis | 32/2530 | 53/8465 | 3.82e-06 | 4.10e-05 | 2.53e-05 | 32 |
| hsa0051311 | Liver | Cirrhotic | Various types of N-glycan biosynthesis | 26/2530 | 42/8465 | 1.65e-05 | 1.41e-04 | 8.69e-05 | 26 |
| hsa0051021 | Liver | HCC | N-Glycan biosynthesis | 40/4020 | 53/8465 | 2.95e-05 | 1.87e-04 | 1.04e-04 | 40 |
| hsa005132 | Liver | HCC | Various types of N-glycan biosynthesis | 30/4020 | 42/8465 | 1.41e-03 | 5.07e-03 | 2.82e-03 | 30 |
| hsa0051031 | Liver | HCC | N-Glycan biosynthesis | 40/4020 | 53/8465 | 2.95e-05 | 1.87e-04 | 1.04e-04 | 40 |
| hsa005133 | Liver | HCC | Various types of N-glycan biosynthesis | 30/4020 | 42/8465 | 1.41e-03 | 5.07e-03 | 2.82e-03 | 30 |
| hsa005105 | Oral cavity | OSCC | N-Glycan biosynthesis | 39/3704 | 53/8465 | 9.77e-06 | 4.36e-05 | 2.22e-05 | 39 |
| hsa005135 | Oral cavity | OSCC | Various types of N-glycan biosynthesis | 29/3704 | 42/8465 | 8.03e-04 | 2.32e-03 | 1.18e-03 | 29 |
| hsa0051012 | Oral cavity | OSCC | N-Glycan biosynthesis | 39/3704 | 53/8465 | 9.77e-06 | 4.36e-05 | 2.22e-05 | 39 |
| hsa0051312 | Oral cavity | OSCC | Various types of N-glycan biosynthesis | 29/3704 | 42/8465 | 8.03e-04 | 2.32e-03 | 1.18e-03 | 29 |
| hsa0051022 | Oral cavity | LP | N-Glycan biosynthesis | 31/2418 | 53/8465 | 4.86e-06 | 4.14e-05 | 2.67e-05 | 31 |
| hsa0051321 | Oral cavity | LP | Various types of N-glycan biosynthesis | 22/2418 | 42/8465 | 9.58e-04 | 4.49e-03 | 2.90e-03 | 22 |
| hsa0051032 | Oral cavity | LP | N-Glycan biosynthesis | 31/2418 | 53/8465 | 4.86e-06 | 4.14e-05 | 2.67e-05 | 31 |
| hsa0051331 | Oral cavity | LP | Various types of N-glycan biosynthesis | 22/2418 | 42/8465 | 9.58e-04 | 4.49e-03 | 2.90e-03 | 22 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ALG12 | SNV | Missense_Mutation | c.389N>A | p.Phe130Tyr | p.F130Y | Q9BV10 | protein_coding | possibly_damaging(0.491) | TCGA-D8-A27P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| ALG12 | SNV | Missense_Mutation | rs751656286 | c.632N>A | p.Arg211His | p.R211H | Q9BV10 | protein_coding | possibly_damaging(0.671) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| ALG12 | SNV | Missense_Mutation | rs752687068 | c.884N>T | p.Ala295Val | p.A295V | Q9BV10 | protein_coding | benign(0.19) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ALG12 | SNV | Missense_Mutation | rs149109851 | c.776N>T | p.Pro259Leu | p.P259L | Q9BV10 | protein_coding | probably_damaging(1) | TCGA-EI-6882-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| ALG12 | insertion | In_Frame_Ins | novel | c.820_821insCTG | p.Cys274delinsSerGly | p.C274delinsSG | Q9BV10 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| ALG12 | SNV | Missense_Mutation | novel | c.609G>T | p.Lys203Asn | p.K203N | Q9BV10 | protein_coding | benign(0.033) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| ALG12 | SNV | Missense_Mutation | rs769555808 | c.1034N>T | p.Ser345Phe | p.S345F | Q9BV10 | protein_coding | possibly_damaging(0.882) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ALG12 | SNV | Missense_Mutation | rs761301009 | c.223G>A | p.Ala75Thr | p.A75T | Q9BV10 | protein_coding | benign(0.277) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| ALG12 | SNV | Missense_Mutation | c.644C>T | p.Pro215Leu | p.P215L | Q9BV10 | protein_coding | possibly_damaging(0.595) | TCGA-AP-A0LP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Hormone Therapy | megace | SD | ||
| ALG12 | SNV | Missense_Mutation | rs367671008 | c.1363N>A | p.Val455Met | p.V455M | Q9BV10 | protein_coding | benign(0.006) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |